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ejects zinc from retroviral nucleocapsid zinc
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Background: Sexual acquisition of the human immunodeficiency virus (HIV) through mucosal transmission may be
prevented by using topically applied agents that block HIV transmission from one individual to another. Therefore,
virucidal agents that inactivate HIV virions may be used as a component in topical microbicides.
Results: Here, we have identified 2-methyl-3-phenyl-2H-[1,2,4]thiadiazol-5-ylideneamine (WDO-217) as a
low-molecular-weight molecule that inactivates HIV particles. Both HIV-1 and HIV-2 virions pretreated with this
compound were unable to infect permissive cells. Moreover, WDO-217 was able to inhibit infections of a wide
spectrum of wild-type and drug-resistant HIV-1, including clinical isolates, HIV-2 and SIV strains. Whereas the capture
of virus by DC-SIGN was unaffected by the compound, it efficiently prevented the transmission of
DC-SIGN-captured virus to CD4+ T-lymphocytes. Interestingly, exposure of virions to WDO-217 reduced the amount
of virion-associated genomic RNA as measured by real-time RT-qPCR. Further mechanism-of-action studies
demonstrated that WDO-217 efficiently ejects zinc from the zinc fingers of the retroviral nucleocapsid protein NCp7
and inhibits the cTAR destabilization properties of this protein. Importantly, WDO-217 was able to eject zinc from
both zinc fingers, even when NCp7 was bound to oligonucleotides, while no covalent interaction between NCp7
and WDO-217 could be observed.
Conclusion: This compound is a new lead structure that can be used for the development of a new series of NCp7
zinc ejectors as candidate topical microbicide agents.
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Human immunodeficiency virus type 1 (HIV-1), the
causative agent of AIDS (Acquired Immune Deficiency
Syndrome), still represents a serious global public health
problem. Although established anti-HIV treatments are
relatively effective, they are sometimes poorly tolerated,
highlighting the need for further refinement of the existing
antiviral drugs and the development of novel anti-HIV strat-
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distribution, and reproduction in any mediuman interesting therapeutic strategy to prevent HIV trans-
mission. Several topical agents for preventing HIV trans-
mission have been described, including i) agents that
inactivate HIV such as detergents (e.g. Nonoxynol-9 or
SAVVYW) or pH modifiers (e.g. BufferGel; ReProtect [1]),
ii) agents that target viral replication (e.g. the reverse
transcriptase inhibitors UC-781, TMC-120, tenofovir) and
iii) agents that target viral entry (e.g. PRO 2000, cellulose
sulfate). With the exception of tenofovir [2], most micro-
bicide candidate drugs that have been subject of large
clinical trials, have proved to be non-effective or even
toxic upon long-term exposure of the vaginal environ-
ment to these products.
The HIV-1 nucleocapsid NCp7 is essential for and
plays multiple roles in virus replication [3]. NCp7tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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viral genomic RNA in the interior of the virion. The
binding of NCp7 to nucleic acids results in their con-
densation and protection from nuclease degradation
[4-6]. Therefore, this nucleoprotein complex protects
the genomic RNA ensuring viral stability. A number of
classes of compounds targeting the retroviral NCp7 have
been described, including, 3-nitrosobenzamide (NOBA)
[7], 2,20-dithiobisbenzamides (DIBA) [8], cyclic 2,20-
dithiobisbenzamides (e.g. SRR-SB3) [9], 1,2-dithiane-4,5-
diol-1,1-dioxide [10], azadicarbonamide (ADA) [11,12],
pyridinioalkanoyl thiolesters (PATEs) [13], bis-thiadia-
zolbenzene-1,2-diamines [14] and S-acyl-2-mercapto-
benzamide thioesters (SAMTs) [15]. The latter class
of compounds was recently considered for testing as
topical microbicide for the prevention of HIV trans-
mission [16]. These SAMT compounds were able to
efficiently prevent vaginal transmission of SHIV upon
exposure of nonhuman primates [17]. Here, we have
identified a low-molecular-weight molecule, 2-methyl-
3-phenyl-2H-[1,2,4]thiadiazol-5-ylideneamine, WDO-217,
that inhibits HIV replication. Mechanism-of-action studies
reveal WDO-217 as a potent NCp7 zinc ejector that dir-
ectly inactivates HIV-1 and HIV-2 virions and inhibits the
transmission of DC-SIGN captured virus to CD4+ lym-
phocytes. WDO-217 qualifies as a potential microbicide
lead compound for further (pre)clinical studies.
Results and discussion
Inhibition of HIV and SIV in cell culture
2-Methyl-3-phenyl-2H-[1,2,4]thiadiazol-5-ylideneamine (WDO-
217) (Figure 1) was identified in a high-throughput
screen for anti-HIV and anti-SIV activity in cell culture
(Figure 2 and Table 1) [18,19]. WDO-217 was equally ac-
tive against HIV-1 (IIIB) (EC50: 5 ± 3 μM), HIV-2 (ROD)
(EC50: 2.3 ± 0.3 μM), and SIV (Mac251) (EC50: 5 ± 1 μM),Figure 1 Chemical structure of WDO-217. Molecular weight: 191.25.while its 50% cytotoxic concentration in MT-4 cell cul-
tures was around 72 μM resulting in an average selective
index of approximately 20. Its antiretroviral activity was
confirmed in human T-lymphocyte CEM cell cultures
(Table 2). In contrast, the compound was inactive against
the replication of viruses other than retroviruses, includ-
ing CMV, HSV, VZV, VSV, RSV.
To assess the potential of WDO-217 against drug-
resistant HIV-1 strains, its antiviral activity was exam-
ined against virus strains that are resistant to either
the entry inhibitor dextran sulfate, the CXCR4 antag-
onist AMD3100, the NRTI AZT, or the NNRTI nevira-
pine. Therefore, Jurkat A72 cells containing LTR-GFP
[20] were infected with the respective drug-resistant
virus strains in the presence of the test compound.
Production of Tat protein as a result of viral replica-
tion drives the integrated LTR to produce GFP.
Infected cells become brightly fluorescent and can be
measured by flow cytometry, providing a direct and
quantitative marker for HIV-1 infection in individual
live cells. Cells were harvested 3 days after infection,
and the number of GFP-expressing cells was moni-
tored. Toxicity of the compounds was assessed from
an MTT-based viability assay. WDO-217 invariably
retained its full anti-HIV activity against the different
virus strains (Table 3) whereas dextran sulphate,
AMD3100, AZT, and nevirapine markedly lost inhibi-
tory potential against their respective resistant HIV-1
mutants. These results incited us to carry out a
detailed study on the target of antiviral action of
WDO-217.
Inactivation of HIV-1, including clinical isolates, and HIV-2
virions by 2-methyl-3-phenyl-2H-[1,2,4]thiadiazol-5-
ylideneamine
To explore the direct effect of WDO-217 on virus parti-
cles, HIV-1IIIB or HIV-2ROD was incubated for 1 h at
37°C in the presence or absence of different concentra-
tions of the compound. Then the virus was diluted to
such extent that the residual compound concentration
was far below its antiviral effective concentration, and
this diluted virus amount was used to infect MT-4 cell
cultures. Virus infectivity was determined by titration
and CCID50 calculation (Table 4). WDO-217 attenuated
both HIV-1 and HIV-2 infectivity, as did the Triton X-
100 control, a detergent commonly used in laboratory
practice to inactivate HIV. When the virus was incu-
bated at compound concentrations of 26, 130 and
650 μM WDO-217, it was no longer able to infect cells,
indicating that these concentrations were able to entirely
inactivate the HIV virions. Similar results were obtained
with 0.5% Triton-X-100. In contrast, AZT, an inhibitor
of the HIV reverse transcription that is inhibiting the
viral replication [21], but not directly inactivating HIV
Figure 2 Dose-dependent inhibitory effect of WDO-217 on the replication of HIV-1 IIIB, HIV-2 ROD, and SIV Mac251. MT-4 T-cells were
infected with the respective viruses and incubated in the presence of compound. Protection against HIV-induced cytopathic effect was
monitored 5 days after infection using the MTT-assay [18]. Cell viability in the presence of compound but in the absence of virus, was measured
in parallel. Results are presented as mean ± std dev from at least 2 independent experiments each in triplicate.
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this assay. This demonstrates that the compound is suffi-
ciently diluted during the procedure and no significant
amount of residual AZT is retained in the sample during
titration for CCID50 determination.
The same experiment was repeated for clinical isolates
from different HIV-1 subtypes of group M. Virus was
incubated in the presence or absence of WDO-217 for
1 hour at 37°C, and virus infectivity was determined by
titration on freshly isolated PBMCs from a healthy
donor. WDO-217 was able to also inactivate these clin-
ical HIV-1 isolates (Table 5).
Effect of 2-methyl-3-phenyl-2H-[1,2,4]thiadiazol-5-
ylideneamine on the capture of HIV-1 by Raji/DC-SIGN cells
and on subsequent virus transmission to CD4+ T cells
Because WDO-217 has virucidal properties, we next
investigated whether it was able to prevent the DC-Table 1 Antiretroviral activity and cytotoxicity of WDO-
217 in the MT-4/MTT-assay
Compound EC50 (μM) CC50
(μM)HIV-1 IIIB HIV-2 ROD SIV Mac251
WDO-217 7.9 ± 3.3 2.3 ± 0.3 5.3 ± 1.5 72 ± 11
AZT 0.007 ± 0.001 0.005 ± 0.0008 0.016 ± 0.007 >35
Values are presented as mean ± std dev from at least 3 independent
experiments.
EC50: 50% effective concentration, concentration of inhibitor required for 50%
inhibition of viral replication.
CC50: 50% cytotoxic concentration, concentration of inhibitor that kills 50% of
the cells.SIGN-mediated virus capture and subsequent transmis-
sion to CD4+ T cells, in view of its potential use as a
microbicide candidate drug. First, the capacity of WDO-
217 to prevent capture of HIV-1 (IIIB) by DC-SIGN was
evaluated using Raji/DC-SIGN cells abundantly expres-
sing DC-SIGN in their cell membranes. Exposure of
Raji/DC-SIGN cells to HIV-1 captured the virus to their
cell membranes, while wild-type Raji/0 cells did not [22].
Virus was pre-exposed to different concentrations of
WDO-217 before it was administered to the Raji/DC-
SIGN cell cultures. After 60 minutes of pre-incubation
with the Raji/DC-SIGN cells, unabsorbed virus and test
compound were carefully removed by repeated washing
steps, and the amount of captured virus was determined
by measurement of the virus-associated p24 content on
the Raji/DC-SIGN cell surface. The α(1-3)/(1-6)-man-
nose-specific plant lectin HHA was included as a
positive control for inhibition of virus capture by Raji/Table 2 Anti-HIV-1 and -HIV-2 activity and cytostatic
properties of WDO-217 in human T-lymphocyte (CEM)
cells
Compound EC50 (μM) CC50
(μM)HIV-1 IIIB HIV-2 ROD
WDO-217 8.3 ± 1.8 15 ± 6.7 94 ± 15
AZT 0.058 ± 0.030 0.055 ± 0.020 >125
EC50: effective concentration or concentration required to protect CEM cells
against the cytopathogenicity of HIV by 50%.
CC50: cytotoxic concentration or concentration compound required to reduce
CEM cell proliferation by 50%.
Values are the mean ± std dev of about 2 to 3 independent experiments.
Table 3 Antiretroviral activity and cytotoxicity of WDO-217 in the anti-HIV
Compound EC50 μM CC50
μMHIV-1 IIIB NL4.3/WT NL4.3/DS5000
R NL4.3/AMD3100R AZTR NNRTIRK103N:Y181C HIV-2 ROD
(165) (>100) (>30) (>85)
WDO-217 1.04 ± 0.2 0.9 ± 0.05 1.2 ± 0.1 1.7 ± 0.9 1.5 ± 0.6 1.3 ± 0.4 1.04 ± 0.3 75 ± 11
GFP-assay in Jurkat cells.
Values are presented as mean ± std dev from at least 3 independent experiments. Fold resistance of mutant strains towards the respective inhibitor of resistant
strains is given in parenthesis (EC50 for NL4.3 wild-type as 1).
EC50: 50% effective concentration, concentration of inhibitor required for 50% inhibition of viral replication.
CC50: 50% cytotoxic concentration, concentration of inhibitor that kills 50% of the cells.
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able to prevent binding of HIV-1 to the Raji/DC-SIGN
cells (Table 6, procedure A), suggesting that the com-
pound does not negatively affect the surface glycopro-
teins of the virus particles and their function.
Next, we evaluated whether WDO-217 could prevent
the transmission of captured HIV-1 from DC-SIGN-
expressing cells to CD4+ T cells. Therefore, the DC-
SIGN+ cells that efficiently captured drug-treated virus
were co-cultured with uninfected C8166 cells. In these
co-cultures, WDO-217 dose-dependently inhibited syn-
cytium formation at an IC50 of 2.2 μM, whereas abun-
dant syncytium formation occurred within 24 to 48 h
post co-cultivation when the captured virus had not
been pre-exposed to the drug (Table 6, procedure B).
When virus was first given the opportunity to be
captured by Raji/DC-SIGN cells in the absence of com-
pound and then the Raji/DC-SIGN cells were co-
cultured with C8166 cells in the presence of various
concentrations of compound, WDO-217 still prevented
the transmission of DC-SIGN-captured virus with an
IC50 value of 8.3 μM. This suggests that WDO-217 can
inactivate virus particles even when they are bound to
DC-SIGN (Table 6, procedure C). All together, these
results demonstrate that 2-methyl-3-phenyl-2H-[1,2,4]
thiadiazol-5-ylideneamine does not inhibit the viral cap-
ture by DC-SIGN but is able to inactivate captured virus
and efficiently prevents the transmission of HIV-1 fromTable 4 Inactivation of isolated HIV particles by WDO-217
Compound CCID50/ml
HIV-1 IIIB HIV-2 ROD
No drug 1 × 106 5.4 × 106
AZT (3.7 μM) 1 × 106 5.4 × 106
Triton X-100 (0.5%) 0 0
WDO-217 (0.2 μM) 5.4 × 106 1.6 × 106
WDO-217 (1 μM) 1.6 × 106 1 × 106
WDO-217 (5 μM) 1 × 106 2.1 × 106
WDO-217 (25 μM) 0 0
WDO-217 (125 μM) 0 0
WDO-217 (625 μM) 0 0
CCID50: 50% cell culture infectious dose as determined by the Reed and
Muench method.DC-SIGN-expressing cells to CD4+ T-lymphocytes,
underlining its potential use as a microbicide agent.
Treatment of HIV-1 with WDO-217 decreases the virion-
associated viral RNA content
To explore the mechanism of HIV inactivation by WDO-
217 in more detail, we investigated the effect of WDO-217
on different viral structural components. Therefore, a pre-
treated and subsequently compound-cleared virus stock
was assessed for both its core p24 antigen protein as well
as its viral genomic RNA content (Figure 3). As expected,
the detergent Triton-X-100 disturbs the structure of the
virions, and no p24 core protein nor viral genomic RNA
could be detected in the isolated virus stock after treat-
ment and subsequent washing. In contrast, treatment with
WDO-217 did not affect the amount of virus-associated
p24 core protein, as for the untreated or AZT-treated con-
trol. However, when the viral genomic RNA content of the
pre-treated virus stock was quantified by real-time RT-
qPCR or visualized by Northern blot, there was a clear de-
crease in viral RNA for the WDO-treated HIV-1 virions as
compared to the untreated control (Figure 3), indicating
that WDO-217 reduces the virion-associated RNA stabil-
ity. Since inside the virion the genomic RNA is protected
by the viral nucleocapsid protein (NCp7), this prompted
us to investigate the effect of WDO-217 on the nucleocap-
sid protein.
Zinc ejection from the retroviral zinc fingers
The zinc-ejecting properties from the NCp7 zinc fingers
by WDO-217 were investigated by monitoring the intrin-
sic fluorescence of the Trp37 residue of NCp7(11-55),
which shows a 3-fold decrease in its fluorescence quantum
yield on zinc removal [23,24]. Addition of a 10-fold excess
of WDO-217 (10 μM) induced the same decrease of
Trp37 fluorescence as observed for 1 mM EDTA, indicat-
ing that WDO-217 efficiently ejects zinc from NCp7(11-
55) (Figure 4A). Subsequently, the zinc ejection from
NCp7(11-55) by WDO-217 exposure was investigated in
function of time (Figure 1B and C). The compound
induced a progressive decrease in Trp37 fluorescence and
zinc ejection was complete after 35 minutes. Ejection of
50% of the zinc is observed in less than 5 minutes
(Figure 4C). A large excess of Zn2+ ions (100-fold excess
Table 5 Inactivation of clinical isolates from different HIV-1 subtypes by WDO-217
CCID50/ml
UG275 ETH2220 UG270 BZ163 BCF-Dioum
subtype A subtype C subtype D subtype F subtype G
untreated control 16242 64969 25781 16242 25781
WDO-217 (125 μM) 2558 2558 6446 2558 2558
CCID50: 50% cell culture infectious dose as determined by titration on PBMCs.
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of WDO-217, since nearly complete ejection of zinc from
NCp7(11-55) was observed after 30 minutes (Figure 4D).
This result suggests that WDO-217 does not directly che-
late zinc ions but progressively ejects the zinc ions from
the NCp7 zinc fingers. All together, our results indicate
that WDO-217 is a very efficient zinc ejector from NCp7.
To further investigate the zinc ejection properties of
WDO-217, we analyzed the changes in the mass of NC
(11-55) by supramolecular mass spectrometry (MS). Purity
and homogeneity of NC(11-55) were verified by mass ana-
lysis in denaturing conditions. In these acidic conditions,
zinc is released from the peptide; and a molecular weight
of 5137. 7 ± 0.4 Da was measured, in agreement with the
expected mass of the zinc-free NC form (5137.9 Da). In
non-denaturing conditions, NC(11-55) analysis revealed
the presence of a unique ion series of 5264.0 ± 0.4 Da cor-
responding to NC(11-55) with 2 zinc ions attached
(Figure 5A). Similar MS experiments were then performed
in the presence of increasing WDO-217 amounts in order
to assess the WDO-127 effect on NC/zinc complexes
(Figure 5B and 5C). In the presence of a 2-fold excess of
WDO-127, three different peaks corresponding to the na-
tive form of NC(11-55) with 2 zinc ions (MW=5264.0 ±
0.4 Da), NC(11-55) with one zinc ion (MW=5195.7 ±
0.1 Da) and the zinc free form of NC(11-55) (MW=
5131.8 ± 0.3 Da) were observed, confirming that WDO-
217 was able to eject zinc (Figure 5B). Using higher WDO-
217 concentrations (five-fold excess of WDO-127 over
NC) led to more efficient zinc ejection, as the major spe-
cies detected (80%) corresponded to the zinc-free form of
NC(11-55). Noticeably, zinc ejection leads to the formationTable 6 Inhibition of HIV-1 NL4.3 capture and transmission* b
Compound
HIV-capture procedure A T
WDO-217 >105
HHA 0.014 ± 0.01
*In co-cultivation with C8166 cells; samples examined after 42 hours of incubation.
Procedure A: HIV was pretreated (1 h) with compound before it was added to Raji/
Procedure B: Raji/DC-SIGN cells were exposed to compound-pretreated (1 h) HIV a
presence of C8166 cells. The read-out of this experiment was the replication capaci
Procedure C: HIV-captured Raji/DC-SIGN cells were cocultivated with C8166 cells in
formation).of three disulfide bridges as suggested from the differences
in molecular weights in denaturing conditions for NC(11-
55) in the absence (5137. 4 ± 0.4 Da) and the presence
(5131. 4 ± 0.6 Da) of WDO-127. Altogether these MS
results unambiguously confirmed that WDO-217 acts as a
zinc-ejector. Interestingly, no covalent complex between
NC(11-55) and WDO-217 was observed in our experimen-
tal conditions (even in very mild MS conditions, Vc = 20 V
and Pi = 6 mbar), suggesting that the interaction between
the two species is likely transient. This is in contrast to the
earlier discovered DIBA zinc ejectors for which the Zn
ejection is accompanied by the formation of covalent com-
plexes formed between the compound and Cys residues of
Zn-depleted NCp7 [25].
Inhibition of NCp7(11-55)-induced destabilization of cTAR
To confirm the zinc ejection, we measured the ability of
NC(11-55) to induce the destabilization of the secondary
structure of cTAR DNA in the presence of WDO-217.
cTAR is the complementary sequence of the transactiva-
tion response element, involved in the minus strand
DNA transfer during reverse transcription [26-28]. The
NC(11-55)-induced destabilization is exquisitely sensi-
tive to the proper folding of the zinc-bound finger motifs
and totally disappears when zinc ions are removed [29].
The NCp7-induced destabilization of cTAR can be sensi-
tively monitored by using the doubly labeled Rh6G-50-
cTAR-30-Dabcyl derivative. In the absence of NCp7,
cTAR is mainly in a non-fluorescent closed form where
the Rh6G and Dabcyl labels, respectively at the 50 and 30
termini of the cTAR stem are in close proximity of each
other [30]. As can be noticed from Figure 6A, and iny Raji/DC-SIGN cells, quantified by p24-ELISA
IC50 (μM)
ransmission procedure B Transmission procedure C
2.2 ± 1 8.3 ± 0.4
0.002 ± 0.001 ≤0.003
DC-SIGN cells. Capture was measured by p24 analysis of the washed cell pellet.
fter which compound was removed and the cells were cocultured in the
ty of virus in C8166 as monitored by p24 analysis.
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Figure 3 Effects of WDO-217 on virion-associated Gag p24 CA
and genomic mRNA content of HIV-1 virus particles. Isolated
HIV-1 particles were incubated with different concentrations of
compounds and subsequently cleared from excess compound by
multiple washing and centrifugation steps. (A) The amount of virion-
associated p24 was quantified by ELISA, and the total virus-
associated genomic RNA was quantified by RT-qPCR. (B) Genomic
RNA of untreated virus (1) or virus treated with 0.5% Triton X-100 (2)
or 125 μM WDO-217 (3) was visualized by Northern blot. (C) Dose
dependent decrease of genomic RNA in treated virus particles as
quantified by RT-qPCR. Concentration of compound used is given
between brackets. Results are mean ± std dev with n = 3.
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cTAR at a 10-fold molar excess led to a melting of the
bottom of the cTAR stem, which increases the distance
between the two fluorophores and thus increases the
Rh6G fluorescence. In line with the zinc ejection hy-
pothesis, preincubation of NC(11-55) with WDO-217 at
a molar ratio of 10:1 in respect with NC(11-55), led to a
full loss of NC(11-55) ability to destabilize cTAR. Inter-
estingly, there was no difference in activity on NCp7-
induced cTAR destabilization by WDO-217 when the
compound was preincubated first with NCp7 or first
with cTAR (Figure 6A). This suggests that WDO-217
can dissociate zinc from NCp7 even when the protein is
bound to nucleic acids. The inhibition of the NC(11-55)-
induced destabilization of cTAR by WDO-217 was fur-
ther monitored as a function of time (Figure 6B). A
complete inhibition was observed after 50 minutes of in-
cubation with WDO-217, and 50% inhibition was
reached in less than 5 minutes in close correlation with
its zinc ejection profile (Figure 6D), further confirming
the effect of WDO-217 on NC(11-55).
Effect of WDO-217 on the interaction of NCp7(11-55) with
SL3 or PBS
To explore the effect of WDO-217 on the nucleic acid bind-
ing properties of NCp7(11-55), we used 3-hydroxyflavone
(3HC) labeled NC(11-55) peptide. The 3HC probe
shows a two-band emission highly sensitive to the bind-
ing of nucleic acids [31]. This two-band emission is the
result of a proton transfer reaction that generates two
excited states: a normal one (N*) and a tautomeric one
(T*). Due to their different dipole moments, these two
forms are differently sensitive to the environment. To
test the binding properties of 3HC-NCp7(11-55), the
SL3 RNA and Δ(-)PBS DNA sequences were selected
since they preferentially bind one NCp7 per oligo-
nucleotide (ODN) [32,33]. SL3 corresponds to the third
stem-loop sequence of the HIV-1 encapsidation se-
quence, while Δ(-)PBS DNA corresponds to the (-) Pri-
mer Binding Site sequence lacking its 30 single strand
overhang. Accordingly, we examined the changes in the
emission spectra of 3HC-NCp7(11-55)/oligonucleotide
Figure 4 Zinc ejection from the NCp7(11-55) zinc fingers by WDO-217. (A) Emission spectra of NCp7(11-55) (1 μM) recorded in the absence
(disks) and the presence of 10 μM WDO-217 (star). As a reference, NCp7(11-55) was treated with 1 mM EDTA, a well known zinc chelator
(triangle). Pre-incubation time of WDO-217 with NCp7(11-55) was 1 hour. (B) Time-dependent zinc ejection from NCp7(11-55). The emission
spectra of NCp7(11-55) (1 μM) were recorded in the absence (disks) and presence of WDO-217 (10 μM) at the different time points as indicated.
(C) Kinetics of zinc ejection after addition of 10 μM WDO-217. The data points (stars) corresponded to the fluorescence intensity at the maximum
emission wavelength from panel B. Solid line represents a double-exponential fit to the data. (D) Zinc ejection from NCp7(11-55) in the presence
of an excess of zinc. Emission spectra of the NCp7(11-55) (1 μM) in the presence of an excess of 100 μM zinc (triangle). Then, 10 μM of WDO-217
was added, and the spectrum was recorded after 30 minutes of incubation (square). The emission spectrum of NCp7(11-55) incubated with 1 mM
EDTA (triangle) for one hour is given as a reference.
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Δ(-)PBS DNA or SL3 RNA to 3HC-NCp7(11-55) was
found to decrease the overall intensity of the 3HC probe
as well as the N*/T* ratio of its two emission bands in re-
spect to the free 3HC-NCp7(11-55) peptide (Figure 7A
and B). This is a result of the stacking of the probe with
the bases and its contact with the ODN backbone in
the peptide/ODN complexes [31]. Addition of WDO-217
induces a further decrease in the intensity of the spectrum,
suggesting that WDO-217 does not dissociate the NCp7/
oligonucleotide complex. This additional decrease in
fluorescence accompanied by a slight increase in the
N*/T* ratio is likely due to a rearrangement of the zinc-
free peptide on the ODN sequence, which leads to a
change in the interaction of the 3HC probe with the
ODN. The increase in the N*/T* ratio observed with the
zinc-depleted complex indicates that the environment of
the 3HC probe is more polar than in the initial 3HC-
NCp7(11-55)/oligonucleotide complex, suggesting a shift
from stacking interactions towards more polar interac-
tions with the backbone.Next, we monitored the changes in the emission
spectrum of 3HC-NCp7(11-55) that was preincubated
with WDO-217 for 30 minutes, before addition to SL3
(Figure 7C). The incubation of 3HC-NCp7(11-55) with
WDO-217 for 30 minutes leads to a decrease in the
overall intensity of the 3HC probe as well as its N*/T*
ratio (from 1.0 to 0.86) in respect with the free 3HC-
NCp7(11-55). This is likely the result of a stronger inter-
action of the 3HC probe with the peptide backbone
when it is in the zinc-free form. Addition of SL3 to the
zinc-depleted 3HC-NC(11-55) induced a further de-
crease of the fluorescence emission resulting in a
spectrum similar to that obtained when WDO-217 was
added to the preformed 3HC-NC(11-55)/SL3 complex
(Figure 7B). This result confirms that WDO-217 is able
to eject zinc from the NC/ODN complex.
WDO-217 does not cause accumulation of unprocessed
Gag polyprotein
When added to infected cells, several NCp7 zinc ejecting
compounds, such as SRR-SB3 [34] and SAMTs [35],
Figure 5 Zinc ejection as monitored by mass spectrometry. Supramolecular mass spectrometry analysis on 20 μM NCp7(11-55) (A) in the
absence of WDO-217 or after 30 min incubation at room temperature with either (B) 40 μM WDO-217 or (C) 100 μM WDO-217 in 50 mM
ammonium acetate, pH7.0. Under non-denaturing conditions (Vc = 20 V, Psi = 6 mbar), the mass measured for NCp7(11-55) alone is 5264.0 Da
corresponding to the NC peptide complexed with two zinc ions. Five times molar excess of WDO-217 leads to approximately 80% zinc ejection.
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preventing Gag precursor protein processing and caus-
ing accumulation of aggregated, unprocessed Gag poly-
protein. Recently, it has been shown that this new
mechanism involves acetylation of the NCp7 region of
Gag, thereby blocking Gag processing [35]. We investigated
whether WDO-217 was able to induce a similar effect when
added to virus-infected cells. For this experiment, HIV-1
IIIB chronically-infected HuT-78 cells were treated with dif-
ferent WDO-217 concentrations. Analysis of the progeny
virus in the supernatant demonstrated that treatment with
WDO-217 did not result in a drastic accumulation of un-
processed Gag polyprotein (Figure 8). As controls, the pro-
tease inhibitor ritonavir and the zinc ejector SRR-SB3 did
effectively increase the appearance of unprocessed Gag.
Conclusion
The retroviral zinc fingers of the HIV-1 NCp7 are
strictly conserved and functionally obligatory in the viral
replication and virion stability. In contrast to the zinc
fingers, the N-terminal domain is less conserved, but the
positions of the basic residues are mainly conserved; also
the basic linker between the two zinc fingers is highly
conserved [36,37]. Early studies have demonstrated that
disruption of the zinc fingers by removal of the zinc led
to a loss of viral replication [38]. Different classes of zinc
ejectors have been reported to efficiently eject zinc from
the NCp7 zinc fingers. More specifically, the N-
substituted S-acyl-2-mercaptobenzamides (SAMTs) aresuggested as candidate pluripotent, HIV-specific, viruci-
dal microbicides [16]. Such nucleocapsid inhibitors were
directly virucidal by preventing the initiation of reverse
transcription and modifying the CCHC amino acid do-
main conformation within Gag [11,39]. Here, we have
identified 2-methyl-3-phenyl-2H-[1,2,4]thiadiazol-5-yli-
deneamine (WDO-217) as a very potent ejector of zinc
ions from the HIV-1 NCp7 zinc fingers, inactivating
HIV-1 and HIV-2 virions and relieving the protection of
the viral RNA by the retroviral nucleocapsid protein.
The exact detailed mechanism by which the RNA is
degraded is currently under study. Interestingly, WDO-
217 is able to dissociate zinc ions from NCp7 even when
it is bound to nucleic acids. In agreement with the com-
parable affinities of the native and zinc-depleted NCp7
forms for oligonucleotides [29,40,41], ejection of zinc
from NCp7 by WDO-217 should not dissociate the pro-
tein from the oligonucleotide. However, a change in the
binding mode is expected since native NCp7 was shown
to strongly interact with the bases of its nucleic acid tar-
gets through van der Waals, H-bonding and stacking
interactions [32,33,42-44], while the zinc-depleted forms
of NCp7 are thought to interact mainly through electro-
static interactions with the phosphate groups of the
DNA or RNA backbone [45,46]. The differences in the
binding modes of the native and zinc-depleted forms
have been clearly evidenced by the fact that only the
former can modify the dynamics of the bases and struc-
turally rearrange the oligonucleotides [32,45,46]. In
Figure 6 Inhibition of NCp7(11-55)-induced cTAR
destabilization by WDO-217. (A) Emission spectra of Rh6G-cTAR-
Dabcyl (0.1 μM) recorded in the absence (circle) or in the presence
of NCp7(11-55) (1 μM) (square). To determine the importance of the
order of addition of the compounds, the emission spectra of Rh6G-
cTAR-Dabcyl (0.1 μM) were recorded either after addition of NCp7
(11-55) preincubated with 10 μM WD0-217 (open triangle) or after
preincubation with 10 μM WDO-217 and then, addition of 10 μM
NCp7(11-55) (closed triangles). Excitation wavelength was 520 nm.
(B) Inhibition kinetics of NC-induced cTAR destabilization by WDO-
217. Emission spectra of Rh6G-cTAR-Dabcyl (0.1 μM) were recorded
in the absence (circle) and in the presence of NCp7(11-55) (1 μM)
(square) and at different times after addition of WDO-217 (10 μM) as
indicated. Excitation wavelength was 520 nm. (C) Correlation
between the kinetics of Zn2+ ejection and inhibition of NC-induced
cTAR destabilization by WDO-217 (10 μM). Inhibition of cTAR
destabilization (triangle) correlates well with zinc ejection (star).
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found not to form a covalent complex with NCp7. This
could be of interest because it would in principle allow
using a lower concentration of compound as one mol-
ecule can react with more than one NCp7 as compared
to compounds that react covalently. A disadvantage of a
non-covalent binder could be that zinc ejection may be
reversible if it is not followed by oxidation of the
cysteines in the zinc fingers. As a consequence, the con-
centration of WDO-217 should be high enough to main-
tain an efficient depletion of zinc, so that oxidation ofcysteines will occur. Although its antiviral selectivity is
somewhat moderate, WDO-217 represents the first lead
compound among zinc-ejecting compounds with a
unique mode of action. Due to its moderate therapeutic
index this lead compound would be more appropriate as
microbicide then as a systemic therapeutic agent. Future
structure activity relationship studies and molecular
modeling studies, however, will likely enable improve-
ment on activity, selectivity and pharmacological proper-
ties of the compound. Although WDO-217, as such, is a
simple molecule there is room for further modifications
and subsequent SAR studies. Modifications are possible
introducing substituents at different positions on the
phenyl ring. It is certainly worthwhile to further investi-
gate the importance of the relative positions and nature
of the substituents on the 1,2,4-thiadiazol ring. Furthermore
it would be interesting switching to other heterocyclic rings,
the most obvious being a series of 4,5-disubstituted -2-
aminothiazole derivatives.
Interestingly, WDO-217 treatment does not inhibit the
direct gp120-mediated capture of virus on DC-SIGN
suggesting that it is able to inactivate HIV but with a
preservation of the conformational and functional integ-
rity of the surface envelope proteins. This preservation
of surface proteins has earlier been demonstrated with
the prototypical NCp7 zinc ejector AT-2 [47]. Moreover,
WDO-217 inactivates virus particles even when they are
bound to DC-SIGN and prevents the transmission of DC-
SIGN-captured HIV to CD4+ cells. This makes WDO-217
suitable, not only as a valuable component in topical
microbicides, but also for the inactivation of virions to be
used as vaccine antigens [47]. Indeed, HIV vaccine strat-
egies using DCs are currently being investigated. DCs de-
tect viruses in peripheral tissues and, following activation
and virus capture/uptake, migrate to lymph nodes to trig-
ger adaptive immune responses [48]. However, HIV is able
to modulate these DCs to facilitate infection and transmis-
sion to T-cells causing their disregulation [49]. This
Figure 7 Effect of WDO-217 on the interaction of NCp7(11-55)
with SL3 or PBS. (A) Effect of WDO-217 on the emission spectra of
3HC-NC(11-55) complexed with ΔP(-)PBS. Emission spectra of 3HC-
NC (0.2 μM) in the absence (square) and in the presence of ΔP(-)PBS
(0.2 μM)(disk). For monitoring the effect of 10 μM WDO-217, the
spectra were recorded immediately after its addition to the complex
(triangle) and after 30 minutes (star). (B) Effect of WDO-217 on the
emission spectra of 3HC-NCp7(11-55) complexed with SL3 RNA.
Conditions and symbols are as in A. (C) Importance of the order of
addition of the reactants on the emission spectra of 3HC-NCp7(11-
55) complexed with SL3. The emission spectra of 3HC-NC(11-55)
(0.2 μM) in the absence (square) and in the presence of WDO-217
(10 μM) (circle). SL3 (0.2 μM) was added to 3HC-NCp7(11-55)
(0.2 μM) pre-incubated with WDO-217 (10 μM) for 30 minutes
(triangle). Spectra were recorded in 10 mM phosphate buffer,
100 mM NaCl, pH 7.0. Excitation wavelength was 340 nm.
Figure 8 WDO-217 does not cause accumulation of
unprocessed Gag polyprotein. HIV-1 IIIB virions from persistently
infected HuT-78 cells treated with different concentrations of
compound were analysed by gel electrophoresis and
immunoblotted with antibody against capsid. 1: untreated; 2: AZT
(3.7 μM); 3: ritonavir (2.7 μM); 4: WDO-217 (50 μM); 5: WDO-217
(25 μM); 6: SRR-SB3 (75 μM); 7: SRR-SB3 (15 μM).
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modulation and disregulation. In this respect, WDO-217
appears of high interest, since it does not prevent the cap-
ture by DC SIGN but prevents subsequent transmission
and infection.
This new compound is useful as a lead for the design
of a future new generation NCp7 inhibitors that couldbe applied as an agent in microbicide formulations and
vaccine strategies.Methods
Cells and viruses
MT-4, Jurkat A72, CEM, HuT-78 and Raji/DC-SIGN
cells were grown and maintained in RPMI 1640 supple-
mented with 10% heat-inactivated fetal calf serum,
2 mM L-glutamine, 0.1% sodium bicarbonate and 20 μg
gentamicin per ml. The HIV-1(IIIB) strain was provided
by R.C. Gallo and M. Popovic (at that time at the NIH,
Bethesda, MD, USA). HIV-2(ROD) was obtained from L.
Montagnier (at that time at the Pasteur Institute, Paris,
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were kindly provided by L. Burleigh (Paris, France).In vitro antiviral assays
Evaluation of the antiviral activity of the compounds
against HIV-1 strain IIIB in MT-4 cells was performed
using the MTT assay as previously described [18,19].
Stock solutions (10 x final concentration) of test com-
pounds were added in 25 μl volumes to two series of
triplicate wells so as to allow simultaneous evaluation of
their effects on mock- and HIV-infected cells at the be-
ginning of each experiment. Serial 5-fold dilutions of test
compounds were made directly in flat-bottomed 96-well
microtiter trays using a Biomek 3000 robot (Beckman
instruments, Fullerton, CA). Untreated HIV- and mock-
infected cell samples were included as controls. HIV-1
(IIIB) stock (50 μl) at 100-300 CCID50 (50% cell culture
infectious doses) or culture medium was added to either
the infected or mock-infected wells of the microtiter
tray. Mock-infected cells were used to evaluate the
effects of test compound on uninfected cells in order to
assess the cytotoxicity of the test compounds. Exponen-
tially growing MT-4 cells were centrifuged for 5 minutes
at 220 g, and the supernatant was discarded. The MT-4
cells were resuspended at 6 x 105 cells/ml and 50 μl
volumes were transferred to the microtiter tray wells.
Five days after infection, the viability of mock-and HIV-
infected cells was examined spectrophotometrically using
the MTT assay. The MTT assay is based on the reduction
of yellow coloured 3-(4,5-dimethylthiazol-2-yl)-2,5-diphe-
nyltetrazolium bromide (MTT) (Acros Organics) by mito-
chondrial dehydrogenase activity in metabolically active
cells to a blue-purple formazan that can be measured
spectrophotometrically. The absorbances were read in an
eight-channel computer-controlled photometer (Infinite
M1000, Tecan), at two wavelengths (540 and 690 nm). All
data were calculated using the median absorbance value of
three wells. The 50% cytotoxic concentration (CC50) was
defined as the concentration of the test compound that
reduced the absorbance (OD540) of the mock-infected
control sample by 50%. The concentration achieving 50%
protection against the cytopathic effect of the virus in
infected cells was defined as the 50% effective concentra-
tion (EC50).
The antiviral activity of the compounds against HIV
was evaluated in Jurkat cells stably transformed to ex-
press the LTR-GFP (A72 cells) [20,50]. In 96-well plates,
3 × 104 A72 cells were infected with HIV in the presence
of various concentrations of test compound. Three days
post infection, cells were harvested and fixed in 3% par-
aformaldehyde. GFP-expression was quantified on a sin-
gle cell basis by flow cytometry [51,52]. Toxicity of the
compounds was tested using an MTT-based method.HIV-1 core antigen (p24 Ag) in the supernatant was
analyzed by the p24 Ag enzyme-linked immunosorbent
assay (Perkin Elmer).
Virucidal assay
Aliquots of a HIV stock (IIIB or ROD) were incubated with
various concentrations of compound in a final volume of
100 μl RPMI-1640 culture medium with 10% FCS for
1 hour at 37°C. For the clinical isolates of different clades,
stock was incubated with 125 μM WDO-217 for 1 hour
at 37°C. Subsequently, the samples were diluted 4000
times with complete medium so that the residual concen-
tration of compound present was far below its IC50. The
drug-treated and diluted virus suspension was then used
to infect susceptible MT-4 T-cells to quantify the viral in-
fectivity by titration and CCID50 calculation [53]. The dif-
ferent clinical isolates were titrated on freshly isolated
PBMCs from a healthy donor. Control experiments with
AZT indicated that this procedure effectively diluted the
compound to concentrations well below its effective anti-
viral concentration.
Inhibitory effect on virus production from HuT-78/IIIB
persistently infected cells, virion analysis and western blot
Chronically-infected HIV-1 IIIB HuT-78 cells (HuT-78/
IIIB) were washed four times with PBS to remove all free
virions before treatment and 2 × 105 cells were resus-
pended in 1 ml compound-containing medium for
43 hours at 37°C. Then, virions were prepared from clari-
fied supernatants (10 min at 300 g) by centrifugation at
36670 g for 2 hours at 4°C. Protein from lysed virions were
separated by SDS-PAGE on a NuPageW Novex 4-12%
Bis-Tris gel (Invitrogen) and transferred on a hydrophobic
polyvinylidene difluoride (PVDF) membrane (Amersham
Hybond™-P). The blot was blocked overnight at 4°C by
5% dry milk powder in Western blot wash solution
(WBWS; PBS + 0.5% Tween 20), washed three times for
5 minutes with WBWS and incubated with a mouse anti-
HIV-1 p24 antibody (1:5000) from Abcam. The blot was
then washed three times for 5 minutes with WBWS and
incubated for 1 h with a goat anti-mouse IgG-HRP sec-
ondary antibody (1:2500) from Santa Cruz Biotechnology.
The blot was washed three times for 5 minutes with
WBWS and after 5 minutes of incubation with Super-
Signal West Pico Chemiluminescent Substrate (Thermo
Scientific) it was developed.
Effect of WDO-217 on the exposure of HIV-1 to Raji/DC-
SIGN cells
In a first set of experiments (procedure A), HIV-1 (NL4.3)
was exposed to WDO-217 at 105 μM (in 0.5 ml culture
medium) for 60 minutes at 37°C. Then, 0.5 ml exponen-
tially growing Raji/DC-SIGN cells (106 cells) was added,
and the suspension further incubated at 37°C for
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the cell suspension was centrifuged at 300 g for 10 minutes.
The obtained pellet was washed again with 40 ml medium
and after centrifugation, the cell pellet (containing DC-
SIGN-bound virus) was analyzed for p24 antigen content
by ELISA. In a second set of experiments (procedure B),
Raji/DC-SIGN cells treated as in procedure A were co-
cultured in the presence of an equal amount of C8166 cells
(106 cells) (total volume of 1 ml). Replication in C8166 was
measured after ~ 20 hr of incubation. In a third set of
experiments (procedure C), Raji/DC-SIGN cells were given
the opportunity to capture HIV-1/NL4.3 by mixing Raji/
DC-SIGN cells with virus (106 cells/ml). After one hour of
incubation at 37°C, C8166 cells (106 cells/ml) were added
in the presence of WDO-217 at different concentrations
and giant cell formation in the cultures was examined
microscopically after approximately 24 hr. In the above-
described experiments, the mannose-binding entry inhibi-
tor HHA was included as a reference compound.Quantitative RT-PCR
Total mRNA from virus stock was extracted using the
QIamp viral RNA kit (Qiagen) followed by DNA digestion
using RNase-free DNase I (Invitrogen). DNase I treated
mRNA was used to generate cDNA along with Thermo-
script reverse transcriptase (Invitrogen) and oligo(dT)20.
qRT-PCR for genomic unspliced HIV mRNA was per-
formed according to a protocol described earlier [54],
using 0.2 mM primers TCAGCCCAGAAGTAATACCC
ATGT and TGCTATGTCAGTTCCCCTTGGTTCTCT,
and 0.2 mM FAM-BHQ1 fluorescent probe ATTAACAG
AAGGAGCCACCCCACAAGA. Control reactions omit-
ted reverse transcriptase, and the number of cDNA copies
was determined using a HIV-1NL4.3 molecular clone DNA
standard.Zinc ejection and inhibition of NC(11-55)-induced
destabilization of cTAR monitored by fluorescence
techniques
The NC(11-55) peptide was synthesized by solid phase
peptide synthesis on a 433A synthesizer (ABI, Foster City,
CA), as previously described [31]. The lyophilized peptide
was dissolved in water, and its concentration was deter-
mined using an extinction coefficient of 5,700 M–1 x cm–1
at 280 nm. Next, 2.5 molar equivalents of ZnSO4 were
added to the peptide and pH was raised to its final value,
by adding buffer. The increase of pH was done only after
zinc addition to avoid oxidization of the zinc-free peptide.
Zinc ejection was monitored through the changes in the
intrinsic fluorescence of the Trp37 residue of NC(11-55)
[23,24], after addition of a 10-fold excess of WDO-217
(10 μM) to 1 μM NC(11-55).To monitor the inhibition by WDO-217 of the NC(11-
55)-induced destabilization of cTAR, we used doubly la-
belled cTAR, synthesized at a 0.2 μmol scale by IBA
GmbH Nucleic Acids Product Supply (Göttingen,
Germany). The 50 terminus of cTAR was labeled with 6-
carboxyrhodamine (Rh6G) via an amino-linker with a six
carbon spacer arm. The 30 terminus of cTAR was labeled
with 4-(40-dimethylaminophenylazo)benzoic acid (Dabcyl)
using a special solid support with the dye already attached.
The doubly labeled cTAR was purified by reverse-phase
HPLC and polyacrylamide gel electrophoresis. An extinc-
tion coefficient at 260 nm of 521,910 M–1 x cm–1 was used
for cTAR. All experiments were performed at 20°C in
25 mM Tris–HCl, pH 7.5, 30 mM NaCl, and 0.2 mM
MgCl2 [28]. The effect of WDO-217 on the NC(11-55)-
induced destabilization of cTAR was observed after
addition of 10 μM WDO-217 to 0.1 μM Rh6G-cTAR-
Dabcyl preincubated with 1 μM NC(11-55).
Absorption spectra were recorded on a Cary 400 spectro-
photometer. Fluorescence spectra were recorded at 20°C
on a Fluorolog spectrofluorometer (Horiba, Jobin-Yvon),
equipped with a thermostated cell compartment. Excitation
wavelength was 295 nm and 520 nm, for NC(11-55) and
Rh6G-50-cTAR-30-Dabcyl, respectively. The spectra were
corrected for dilution and buffer fluorescence. The protein
spectra were additionally corrected for screening effects
due to the zinc ejecting agent, using:
IP ¼ Im ∗
dp þ ds þ dr=2
 
1 10dp 
dp 1 10 dpþdsþdr=2ð Þ
 
ð1Þ
where Im is the measured fluorescence of the protein, Ip
is the fluorescence intensity of the protein in the absence of
inner filter, dp is the absorbance of the protein, ds is
the absorbance of WDO-217 at the excitation wavelength,
and dr is the absorbance of WDO-217 at the emission
wavelengths.
Zinc ejection monitored by supramolecular mass
spectrometry
Before mass spectrometry (MS) analysis, NC(11-55) was
dissolved and buffer exchanged with 50 mM ammonium
acetate pH 7.0 using 4 cycles of microcentrifuge size ex-
clusion filtering (Vivaspin 500 5kD, Sartorius Stedim
biotech, Aubagne, France) and peptide concentration
was measured by a Bradford assay.
ESI-MS measurements were performed in the positive
ion mode on an electrospray time-of-flight mass spec-
trometer (LCT, Waters, Manchester, UK) equipped with
an automated chip-based nanoESI source (Triversa
Nanomate, Advion Biosciences, Ithaca, NY). Calibration
of the instrument was performed using multiply charged
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analysis in denaturing conditions, samples were diluted
to 2 μM in a 1/1 water/acetonitrile mixture (v/v) acid-
ified with 1% formic acid and standard interface para-
meters were used to obtain best mass accuracy. In these
conditions, noncovalent interactions are disrupted,
allowing the measurement of the molecular weight of
the monomer with a good accuracy (better than 0.01%).
Analyses under non-denaturing conditions were carried
out after careful optimization of instrumental settings to
avoid dissociation of noncovalent bonds and obtain sens-
ible detection of protein/zinc complexation states. The ac-
celerating voltage (Vc) was fixed to 20 V, and the pressure
in the first pumping stage of the instrument (Pi) to 6 mbar.
Zinc ejection measurements were performed after 30 min-
utes incubation at room temperature of a 20 μM solution
of NC(11-55) with either 40 μM or 100 μM WDO-217.
Data analysis was performed with the MassLynx 3.5 soft-
ware (Waters, Manchester, UK). Peak intensities were
used to estimate the ratios of the different ions detected.
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